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Abstract
Background: Tuberculosis rapid molecular assays, including GeneXpert MTB/RIF® and Loopamp MTBC Detection
Kit®, are highly sensitive and specific. Such performance does not automatically translate in improved disease
control and highly depends on their use, local epidemiology and the diagnostic algorithms they’re implemented
within. We evaluate the performance of both assays and assess their impact on additional cases notification when
implemented within WHO recommended tuberculosis diagnostic algorithms in Madagascar.
Methods: Five hundred forty eight presumptive pulmonary tuberculosis patients were prospectively recruited
between November 2013 and December 2014 in Antananarivo, Madagascar, a high TB incidence sub-Saharan
African urban setting. Both molecular assays were evaluated as first line or add-on testing following negative smear
microscopy. Based on locally defined assay performance characteristics we measure the impact of both assays and
WHO-recommended diagnostic algorithms on additional tuberculosis case notifications.
Results: High sensitivity and specificity was confirmed for both GeneXpert MTB/RIF® (86.6% (95% CI 81.1–90.7%)
and 97.4% (95% CI 94.9–98.8%)) and Loopamp MTBC Detection Kit® (84.6% (95% CI 78.9–89.0%) and 98.4% (95% CI
96.2–99.4%)). Implementation of GeneXpert MTB/RIF® and Loopamp MTBC Detection Kit® increased tuberculosis
diagnostic algorithms sensitivity from 73.6% (95% CI 67.1–79.3%) up to 88.1% (95% CI 82.8–91.9%). This increase was
highest when molecular assays were used as add-on testing following negative smear microscopy. As add-on
testing, GeneXpert MTB/RIF® and Loopamp MTBC Detection Kit® respectively improved case detection by 23.8 and
21.2% (p < 0.05).
Conclusion: Including GeneXpert MTB/RIF® or Loopamp MTBC Detection Kit® molecular assays for TB detection on
sputum samples from presumptive TB cases can significantly increase case notification in TB diagnostic centers. The
TB case detection rate is further increased when those tests are use as second-line follow-on testing following
negative smear microscopy results. A country wide scale-up and digital integration of molecular-based TB diagnosis
assays shows promises for TB control in Madagascar.
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Background
In 2017, an estimated 10.0 millions people fell ill with
tuberculosis (TB) and approximately 3.6 millions of
those went undiagnosed therefore perpetuating the glo-
bal epidemic [1]. Accurate point-of-care diagnostics are
needed to rapidly identify TB cases among presumptive
cases, initiate therapy and interrupt person-to-person
transmission. Despite lower sensitivity and specificity as
compared to novel molecular-based assays, sputum
smear microscopy remains the most commonly used TB
diagnosis tool globally because of its affordability and
potential for implementation at point-of-care. To bypass
the inconvenient delays and biosecurity requirements
associated with bacterial culture, GeneXpert MTB/RIF®
(Cepheid; USA) polymerase chain reaction (PCR) and
Loopamp MTBC Detection Kit® (Eiken Chemical Co;
Japan) loop-mediated isothermal amplification (LAMP)-
based molecular assays were developed, validated on
direct sputum samples and endorsed by the World
Health Organization (WHO) respectively in 2013 and
2016 [2, 3]. Those assays can either be used as first-line
testing in place of sputum smear microscopy or as a
follow-on test in adults with symptoms of pulmonary
TB but testing negative on smear microscopy [4, 5].
Assays impact on case notifications can vary with
context-specific factors including, disease prevalence,
population age distribution, HIV rates and implemented
diagnosis algorithms.
The objective of this study was to evaluate the
diagnostic performance of GeneXpert MTB/RIF® and
Loopamp MTBC Detection Kit® assays and assess
their impact on case detection when implemented as
stand-alone assays for first-line testing or as a follow-
on test following negative sputum smear microscopy
testing.
Methods
Study design
The study participants were recruited in the ‘Établisse-
ment Universitaire de Soins et de Santé Publique’ of
Antananarivo between November 1st, 2013 and December
31st, 2014. This healthcare center is part of the National
Tuberculosis Control Program (NTP) laboratory network
and is audited by the NTP as part of its quality assurance
program. Patients 15 years and older were considered for
inclusion. Eligible patients were those presenting TB
symptoms warranting TB testing as per national guide-
lines, namely cough for more than 3 weeks with or
without hemoptysis and one other TB symptom, such as
fever, night sweats, or recent weight loss [6]. Upon inclu-
sion, two (2) morning sputum samples were collected for
laboratory testing along with basic epidemiological and
clinical data including age, gender and clinical symptoms.
Previous or ongoing TB treatment or incapacity to
produce at least 4 ml of sputum twice served as exclusion
criteria. The study was approved by the ethics committee
from the Ministry of Public Health in Madagascar
(approval number 102-MSANP/CE). Written informed
consent was obtained from all included participants.
Mycobacterium tuberculosis detection testing
All samples were tested in parallel using Lowenstein-
Jensen (LJ) solid culture, auramine fluorescence smear
microscopy, GeneXpert MTB/RIF®, and Loopamp
MTBC Detection Kit®. All assays were performed by
trained laboratory technicians according to manufac-
turer’s recommendations and including positive and
negative controls where applicable. Results were
interpreted blindly with respect to collateral testing.
Fluorescence microscopy was performed and quantita-
tively interpreted on two immediate consecutive
morning sputum samples according to laboratory best
practice [7, 8]. Loopamp MTBC Detection Kit® com-
mercial LAMP assay was performed on the first spu-
tum sample. In brief, DNA was extracted from 60 μl
of sputum during cyclic heating and adsorption steps.
Isothermal amplification was then performed using
two sets of four primers targeting six distinct gyrB
gene and insertion sequences regions of M. tubercu-
losis complex genome. Test result interpretation relies
on amplified product visualization under UV irradi-
ation [9, 10]. Study samples were tested prospectively
without batching to emulate a clinical laboratory
workflow. The remaining sputa were stored at 4°C
until being transferred twice weekly to the National
Reference Laboratory. GeneXpert MTB/RIF® assay was
performed on the second sputum sample. Following
sputum homogenization using reaction buffer and
vortex, PCR targeting M. tuberculosis rpoB gene
region was performed in a closed cartridge-based sys-
tem [11]. In case of “error” or “indeterminate” results,
the analysis was repeated on remaining sputum sam-
ple if available. Culture was performed after sample
N-Acetyl-L-Cysteine Sodium Hydroxide decontamin-
ation on the 1st and 2nd collected samples. 200 μl of
dissolved specimen solution was inoculated on LJ
medium and incubated at 37°C for maximum of
twelve weeks [7].
Diagnostic algorithms and country case notification
projections
Three algorithms for the detection of pulmonary TB in
adults were evaluated and compared. Smear microscopy
as stand-alone assay (algorithm 1) was compared to the
two WHO recommended alternatives, namely molecular
testing as a replacement of smear microscopy (algorithm
2) or as a follow-on test for smear negative presumptive
cases (algorithm 3) [4, 5, 11].
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Statistical analysis
Fluorescence microscopy, GeneXpert MTB/RIF® and
Loopamp MTBC Detection Kit® respective diagnostic
score values were the primary outcomes. LJ media
culture was considered as ‘gold standard’ assay for the
analysis. “indeterminate” results on repeated GeneXpert
MTB/RIF® testing were excluded from the assay per-
formance analysis. Performance characteristics of both
molecular assays were assessed differentially in smear-
positive and -negative patients. 95% confidence intervals
(CI) were calculated around every assay performance
value. Two-tailed chi square test was used to assess
performance difference between assays using two-way
alpha value of 0.05. All statistical analyses were
performed using Stata statistical software version 13.1
(StataCorp LP; College Station, Texas).
Results
Study population and samples
548 presumptive pulmonary presumptive TB cases were
consecutively recruited during the 13-months study
period. Sociodemographic and clinical characteristics of
the study population are presented in Table 1 – Study
population sociodemographic and clinical The median
age of the included study population is 40 years old (±16
years old) and the sex ratio is 1.5 (M/F). Chronic cough
(more than 3 weeks) was the main clinical symptom
observed (85%) that is associated with fever in 57% of
the patients (Table 1). Patients were excluded from the
study because of unknown age (n=2, 0.4%) or missing
culture result (n=29, 5,3%). Patients were excluded from
assay specific sub-analyses because of missing smear mi-
croscopy result (n=3, 0,5%) and repeated indeterminate,
invalid or error GeneXpert MTB/RIF® results (n=8, 1,5%)
(Fig. 1 – Clinical samples included in the fluorescence
smear microscopy, GeneXpert MTB/RIF® and Smear
followed by Loopamp MTBC® Detection Kit® performance
evaluation). A total of 201 (38.8%) samples were con-
firmed to be positive for M. tuberculosis on LJ culture.
Assays clinical performance
Using culture as the gold standard assay, the sensitivity
of fluorescence smear microscopy, GeneXpert MTB/RIF®
and Loopamp MTBC Detection Kit® assays was,
respectively, 73.6% (95% CI 67.1-79.3%), 86.6% (95% CI
81.1-90.7%) and 84.6% (95% CI 78.9-89.0%) (Table 2 -
Fluorescence smear microscopy, GeneXpert MTB MTB/
RIF ® and Loopamp MTBC Detection Kit® performance).
Similarly, assays specificity was, respectively, 99.0% (95%
CI 97.1-99.8%), 97.4% (95% CI 94.9-98.8%) and 98.4%
(95% CI 96.2-99.4%). Both GeneXpert MTB/RIF® (p=0.007)
and Loopamp MTBC Detection Kit® were found to be sig-
nificantly more sensitive than microscopy (p=0.001). Be-
tween those two assays, however, no significant difference
in sensitivity and specificity was observed. When restricting
the analysis to smear negative samples, the sensitivity and
specificity of GeneXpert MTB/RIF® and Loopamp MTBC
Detection Kit® assays were, respectively, 54.7% (95% CI
41.4-67.4%) and 97.4% (95% CI 94.9-98.8%), and 54.7%
(95% CI 41.4-67.4%) and 98.4% (95% CI 96.2-99.4%). Op-
positely, among smear positive isolates, the sensitivity of
GeneXpert MTB/RIF® and Loopamp MTBC Detection Kit®
assays, respectively, increased to 98.0% (95% CI 93.9-
99.6%) and 95.3% (95% CI 90.4-97.9%). No difference in
specificity could be assessed in this sub-group since all
smear positive samples were subsequently confirmed to be
positive for M. tuberculosis in culture (Table 1).
Programmatic impact of diagnosis algorithms
Madagascar’s current standard of care (algorithm 1),
which relies on sputum smear microscopy, diagnosed
151 new cases of pulmonary TB among the 517 included
presumptive cases. Implementing a two-step algorithm
in which negative smear microscopy testing is systemat-
ically followed by molecular testing was found to increase
sensitivity and decrease specificity. With GeneXpert
MTB/RIF®, sensitivity increased from 73.6% (95% CI 67.1-
79.3%) to 88.1% (95% CI 82.8-91.9%; p<0.001) and specifi-
city decreased from 99.0% (95% CI 97.1-99.8%) to 96.7%
(95% CI 94.0-98.3%; p=0.040). With Loopamp MTBC
Detection Kit®, sensitivity increased from 73.6% (95% CI
67.1-79.3%) to 88.1% (95% CI 82.8-91.9%; p<0.001) and
specificity decreased from 99.0% (95% CI 97.1-99.8%) to
97.5% (95% CI 95.0-98.8%, p=0.130). Among the 517
included presumptive TB cases, the GeneXpert MTB/RIF®
testing-based algorithm would have yielded 8 poten-
tial false-positive cases whereas Loopamp MTBC
Detection Kit® would have diagnosed 5 such cases, a
difference which was not found to be statistically
Table 1 Study population sociodemographic and clinical
characteristics
Age
Median 40
SDa 16
Gender (n and %)
Female 219 40%
Male 329 60%
Clinical Symptoms (n and %)
Cough 468 85%
Fever 323 59%
Hemoptysia 135 25%
Chest pain 327 60%
Breathlessness 334 61%
Other 57 10%
a SD standard deviation
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significant (p=0.300) (Table 3 - Clinical performance and
programmatic impact of three diagnosis algorithms).
Additional TB case detection
Implementing GeneXpert MTB/RIF® or Loopamp
MTBC Detection Kit® as first-line assays would have led
to total and additional case notifications of 182 and 31
(+20.5%) or 175 and 24 (+15.9%), respectively (Figs. 2
and 3). Using GeneXpert MTB/RIF® or Loopamp MTBC
Detection Kit® as follow-on tests following negative
smear microscopy would have led to detection of 187
and 36 (+23.8%), and 183 and 32 (+21.2%) total and
additional cases, respectively (Fig. 3). The number of
additional cases detected is higher when these tests were
used as follow-on test following negative smear micros-
copy compared to its use in the first-line (3.2% and 5.3%
respectively for GeneXpert MTB/RIF® and Loopamp
MTBC Detection Kit®). This difference between
algorithm 2 and 3 was significant for Loopamp MTBC
Detection Kit® (p = 0.03).
Discussion
The commercial release and WHO endorsement of PCR
and LAMP-based TB nucleic acid detection systems
allowed delocalization of such technologies to point-of-
care laboratories without previous molecular biology
expertise. The capacity of those technologies to rapidly
and accurately identify TB directly from clinical samples
Fig. 1 Clinical samples included in the fluorescence smear microscopy, GeneXpert MTB/RIF® and Smear followed by Loopamp MTBC® Detection
Kit® performance evaluation. Study enrolment and inclusion process
Table 2 Fluorescence smear microscopy, GeneXpert MTB MTB/RIF® and Loopamp MTBC Detection Kit® performance
Diagnosis assay TP TN FP FN Sensitivity Specificity PPV NPV
n n n n % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Fluorescence smear microscopy
Total (n = 514) 148 310 3 53 73.6 (67.1–79.3) 99.0 (97.1–99.8) 98.0 (94.1–99.6) 85.4 (81.4–88.7)
GeneXpert MTB/RIF®
Smear negative (n = 361) 29 300 8 24 54.7 (41.4–67.4) 97.4 (94.9–98.8) 78.4 (62.6–88.9) 92.6 (89.2–95.0)
Smear positive (n = 148) 145 0 0 3 98.0 (93.9–99.6) N/A 100.0 (96.9–100.0) N/A
Total (n = 509) 174 300 8 27 86.6 (81.1–90.7) 97.4 (94.9–98.8) 95.6 (91.4–97.9) 91.7 (88.2–94.3)
Loopamp MTBC Detection Kit®
Smear negative (n = 369) 29 311 5 24 54.7 (41.4–67.4) 98.4 (96.2–99.4) 85.3 (69.4–94.0) 92.8 (89.5–95.2)
Smear positive (n = 148) 141 0 0 7 95.3 (90.4–97.9) N/A 100.0 (96.8–100.0) N/A
Total (n = 517) 170 311 5 31 84.6 (78.9–89.0) 98.4 (96.2–99.4) 97.1 (93.3–99.0) 90.9 (87.4–93.6)
CI confidence interval, FN false negative, FP false positive, N/A not applicable, MTB(C) Mycobacterium tuberculosis complex, NPV negative predictive value, PPV
positive predictive value, RIF rifampicin, TN true negative, TP true positive
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supported their integration as first-line or follow-on
assays for smear-negative presumptive TB [4, 11]. In this
study, we consecutively enrolled 548 pulmonary TB
suspects, in a clinical and laboratory setting which is
representative of the peripheral laboratories where those
platforms would eventually be implemented. We evalu-
ated assays performance using 2 sputum cultures as gold
standard which represents another strength of this study.
Including GeneXpert MTB/RIF® or Loopamp MTBC
Detection Kit® molecular assays in the algorithms for TB
detection can significantly increase the case notifications
in peripheral TB diagnostic centers. This detection rate
is further increased when those tests are use as second-
line follow-on testing after negative smear microscopy
results. The compared diagnosis algorithms did not
include differential TB testing approaches for specific
populations such as children and patients living with
HIV for which the increased sensitivity of molecular
diagnosis platforms is desirable. This represents another
limitation of this study. HIV incidence is low in
Madagascar and the TB-HIV co-infection prevalence
recorded by the National TB program in the same study
center at the same time of this study was less than 1%
[12]. Hence, the presented results still have high internal
Fig. 3 Total and additional pulmonary tuberculosis case notification associated with GeneXpert MTB MTB/RIF® and Loopamp MTBC Detection
Kit®. Additional pulmonary tuberculosis notifications associated with evaluated diagnosis algorithms in Établissement Universitaire de Soins et de
Santé Publique
Fig. 2 Fluorescence smear microscopy, GeneXpert MTB MTB/RIF® and Loopamp MTBC Detection Kit® based diagnosis algorithms. Analytical
performance of three diagnosis algorithms and impact on case notification at study clinic
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validity. Further evaluation of additional case notification
and costs associated with the use of molecular diagnostic
platforms for children should be performed in Madagascar.
The WHO’s End TB Strategy calls for universal access to
drug susceptibility testing for TB patients [13]. The ability
of GeneXpert MTB/RIF® to simultaneously test for both
the presence of TB and rifampin resistance represents an
important comparative advantage of this platform over
Loopamp MTBC Detection Kit® in high MDR-TB preva-
lence settings or sub-populations [3, 14]. The impact of the
difference between simultaneous drug susceptibility testing
at point-of care with GeneXpert MTB/RIF® or sequential
testing in reference laboratory following Loopamp MTBC
Detection Kit® was not assessed in this study.
Delocalizing novel diagnostic assays to peripheral
laboratories and TB clinics may negatively impact assays’
performance, hence the necessity for appropriate train-
ing during the implementation period and continued
quality assurance. GeneXpert MTB/RIF® was confirmed
to be more sensitive and specific than fluorescence
smear microscopy with sensitivity and specificity
reaching 86.6% (95% CI 81.1-90.7%) and 97.4% (95% CI
94.9-98.8%), respectively. These results agree with
pooled median sensitivity of 88.0% (95% CI 83.0-92.0%)
and specificity of 98.0% (95% CI 97.0-99.0%) reported in
a Cochrane Review of fifteen studies assessing the per-
formance of GeneXpert MTB/RIF® on sputum samples
[3]. Similarly, with a sensitivity of 84.6% (95% CI 78.9-
89.0%) and a specificity of 98.4% (95% CI 96.2-99.4%),
Loopamp MTBC Detection Kit® performance was found
comparable to reports observed from the literature [2].
For both molecular assays, this agreement between
locally assessed performance and reported literature data
was maintained when analyzing the smear-positive and
smear-negative sub-groups of isolates. In this study, the
sensitivity of smear microscopy was found to be higher
than usually reported. This could be explained by the
fact that analyses were performed in a national reference
center by highly trained and experienced personnel in a
diagnostic study setting. Unfortunately, this could not be
compared to performance in other Malagasy laboratory
settings because such data were not available. Neverthe-
less the measured added value of both evaluated mo-
lecular assays could be even higher in other settings.
This increased sensitivity of molecular-based diagnosis
algorithm is of particular interest for the global commu-
nity where 3.6 million TB cases still go missing [1, 14].
Among assessed diagnosis algorithms, implementation
of GeneXpert MTB/RIF® as follow-on test, yielded the
most additional cases with 23.8% additional cases per
year. As our data shows, it needs to be emphasized that
maintaining smear microscopy as a first-line screening
assay has added value on case detection even when
implementing new highly sensitive molecular assays.
Given WHO’s estimate that only 52% of TB cases are
diagnosed in Madagascar, this represents a significant
increase [14]. Scaling up molecular diagnostics technolo-
gies in Madagascar’s 219 first-line TB diagnostics center
certainly represents a challenge and innovative sample
transportation systems, continued training and central-
ized proficiency testing programs would need to accom-
pany a potential diagnosis algorithm change. This study
also emphasizes the fact that increased diagnostic assay
performance alone cannot be relied upon to find the
48% missing cases. Other public health approaches
such as active case finding need to be considered to
ensure every presumptive TB case has access to qual-
ity diagnostics [15].
Together with diagnostic assays’ analytical perform-
ance, operational characteristics and costs are factors
which NTP need to consider when designing and imple-
menting diagnosis algorithms. Both molecular assays
were found to be easy to implement in delocalized cen-
ters without extensive laboratory expertise or previous
molecular testing experience. Laboratory results were
lost for 11 (2%) samples resulting in partial or complete
exclusion of these samples from the analysis. This loss of
information occurred between first-line TB clinics and
the National Reference Laboratory and is thus unlikely
to affect linkage to care and clinical management at local
level. Nevertheless, this underlines the importance of
appropriate networking of TB laboratory facilities and
digitalization of results to facilitate surveillance and
diagnosis quality assurance [16]. This study was not
designed to assess the cost-effectiveness of molecular
diagnosis platforms which were reported to have unit
weighted costs of $14.93 USD (GeneXpert MTB/RIF®)
and between $13.78 and $16.22 USD (Loopamp MTBC
Detection Kit®)) [4, 17, 18]. It can be hypothesized that
increased case notification together with rapid treatment
initiation could lead to transmission and incidence
reduction on the long term.
Conclusion
Whether as a first-line assay or as follow-on testing for
smear-negative TB suspects, GeneXpert MTB/RIF® and
Loopamp MTBC Detection Kit® were highly sensitive
and specific for the diagnosis of pulmonary TB in
Madagascar and proved to significantly increase case de-
tection. The TB case detection rate is further increased
when those tests are use as second-line testing following
negative smear microscopy results. These platforms are
already having a positive impact in Madagascar’s district
reference hospitals and now need to be implemented in
more remote first-line TB clinics. Strong laboratory
network infrastructures including reliable transportation
systems, robust proficiency testing and digital results
data management will facilitate this transition.
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